Primed for
breakthrough

We have cultivated a rapidly growing pipeline, with each molecule offering specific and distinct benefits that can be collectively used to cover a range of chronic inflammatory diseases. Our portfolio of differentiated candidates delivers advances in potency, tissue/brain penetration and chemical structural diversity.

Program
Program
Discovery
Discovery
IND-enabling
IND-enabling
Phase 1
P1
Phase 2
P2
NT-0796
Cardiometabolic diseases
Our lead molecule derived from our proprietary chemistry that is unlike any other NLRP3 inflammasome inhibitor in the space. NT-0796 is designed to deliver an intracellular payload directly to the specific immune cell types that drive inflammatory diseases.

In 2024, we completed the Phase 1b/2a randomized, double-blind placebo-controlled study to assessing the effect of NT-0796 on inflammation in obese participants at risk of cardiovascular disease (NCT06129409). Read our press release for more information.
NT-0249
NT-0249 is a brain-penetrant NLRP3 inflammasome inhibitor with excellent potency and optimized development characteristics, allowing us to develop a low-dose therapy with the potential to address chronic inflammatory diseases of the body. NT-0249 is a Phase II-ready asset.
NT-0150
NT-0150 is a novel chemotype built around a pyridazinone structure. It has shown excellent preclinical efficacy across multiple animal models of inflammatory disease, rapidly and robustly reducing brain and peripheral pro-inflammatory cytokines, as well as other neurological markers. Phase 1 SAD/MAD studies of are in progress.
Additional Peripheral/
Neuro Development Candidates
Cardiovascular Study Infographic
Cardiovascular Study Infographic

For more details, read our press release.